London: Thursday, 30 April 2015: For information purposes, Chi-Med hereby notifies the market that as at 30 April 2015, the issued share capital of Chi-Med consisted of 53,299,964 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 53,299,964 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the FCA’s Disclosure Rules and Transparency Rules.
Ends
|
Chi-Med |
Telephone: +852 2121 8200 |
|
Panmure Gordon (UK) Limited |
Telephone: +44 20 7886 2500 |
|
Citigate Dewe Rogerson |
Telephone: +44 20 7638 9571 |
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.
Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.